SIMSA Act would add a new Schedule A to the Controlled Substances Act and give the Attorney General authority to place synthetic analogues on Schedule A on a temporary basis or as a permanent scheduling decision. The bill sets criteria based on chemical similarity to existing controlled substances and predicted central nervous system effects, and it creates a framework for swift scheduling and review.
It also tightens enforcement through enhanced penalties, false labeling provisions, and a registration regime for importers and exporters, while preserving research avenues under defined safeguards.
In practice, the act aims to block importation and domestic production of synthetic analogues by preemptively placing them under Schedule A and by strengthening the tools available to regulators and prosecutors. It also introduces labeling requirements using IUPAC nomenclature, requires registration for those handling Schedule A substances, and builds a pathway for research uses with appropriate oversight.
The package includes conforming amendments and a sentencing-review mechanism to adjust penalties if the scheduling status changes.
At a Glance
What It Does
Establishes Schedule A within the CSA, defines the criteria for a drug or substance to be placed on Schedule A, and creates a pathway for temporary and permanent scheduling. It also adds penalties, labeling requirements, and a new registration regime for importers/exporters of Schedule A substances, plus related conforming amendments.
Who It Affects
Entities involved in import/export of Schedule A substances, including manufacturers, distributors, laboratories, and research institutions; regulatory agencies (DOJ, AG, HHS) responsible for scheduling and oversight; and legal professionals handling compliance and enforcement actions.
Why It Matters
This creates a proactive regulatory framework to curb illicit synthetic analogue activity by broadening the tools for scheduling, enforcement, and traceability, while balancing legitimate research and international obligations.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The SIMSA Act would add a new Schedule A to the CSA and lay out a concrete test for when a drug should be considered Schedule A. The test hinges on whether the substance is imported or offered for import, has a substantially similar chemical structure to a Schedule I–V drug, and has a predicted stimulant, depressant, or hallucinogenic effect on the central nervous system similar to or greater than existing controlled substances.
It also states that Schedule A substances must not be listed elsewhere in the CSA or regulated by other authorities to qualify.
The bill empowers the Attorney General to issue temporary scheduling orders if a substance meets the Schedule A criteria and would help prevent abuse. A temporary order must become effective 30 days after notice in the Federal Register and can last up to five years, with a possible 180-day extension during ongoing proceedings.
A temporary order would be vacated if a permanent scheduling order is issued, or if another scheduling action is taken.Permanent scheduling would follow after a formal review, including input from the Department of Health and Human Services. If HHS determines a temporary Schedule A substance does not warrant control, the Attorney General must terminate the temporary order.
The act also broadens penalties for Schedule A violations under federal drug laws, introduces labeling requirements that use IUPAC nomenclature, and creates a registration regime for importers and exporters of Schedule A substances, with criteria emphasizing public health, compliance with laws, and the potential for legitimate research and industrial uses. Finally, the act includes conforming amendments across related statutes and provides for a limited sentencing-review mechanism if scheduling changes occur after a person is convicted.
The Five Things You Need to Know
The bill adds Schedule A to the CSA and defines criteria based on structure and CNS effects.
Temporary scheduling can be issued by the Attorney General and lasts up to 5 years (with an extension during proceedings).
Permanent scheduling can follow after a 3-year window, with HHS input affecting the outcome.
Penalties for Schedule A violations include up to 20 years’ imprisonment and enhanced penalties if death or serious injury results.
Labeling of Schedule A substances must reflect IUPAC nomenclature, and importers/exporters must obtain registration.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Establishment of Schedule A
This section modifies the CSA to add a new Schedule A. A substance can qualify for Schedule A if it is imported or offered for import, has a chemical structure substantially similar to a controlled substance in Schedules I–V, and has a predicted stimulant, depressant, or hallucinogenic effect on the CNS that is at least as strong as a substance in Schedules I–V. It also contemplates a trigger for temporary or permanent scheduling as circumstances warrant.
Temporary and permanent scheduling of Schedule A substances
This section authorizes the Attorney General to issue temporary scheduling orders when a Schedule A substance meets the criteria and scheduling would help prevent abuse. A temporary order becomes effective after 30 days and lasts up to five years, with a possible 180‑day extension during proceedings. A temporary order is vacated if a permanent order is issued or if another scheduling action occurs. Permanent scheduling may be issued not earlier than three years after the temporary order, and is contingent on scientific review with input from HHS.
Penalties
This section extends penalties under the Controlled Substances Import and Export Act to Schedule A substances, including up to 20 years’ imprisonment for violations, enhanced penalties if death or serious bodily injury results, and higher fines. It also provides escalated penalties for individuals with prior felony drug convictions and requires mandatory terms of supervised release in many cases.
False labeling of Schedule A controlled substances
This section makes it unlawful to import or export Schedule A substances or products containing them without labeling that identifies the Schedule A substance by IUPAC nomenclature. It includes exemptions for products labeled under the Federal Food, Drug, and Cosmetic Act and certain investigational or clinical trial contexts, preserving some flexibility for regulated research and development.
Registration requirements for Schedule A substances
This section adds a new registration pathway for importers/exporters of Schedule A substances, including criteria that the substance will be used for approved research, analytical, or industrial purposes, and that registrations align with public health and international obligations. It sets factors for evaluating public interest, including control against diversion, compliance with law, promotion of innovation, and applicant history.
Additional conforming amendments
This section makes cross-references to Schedule A throughout related laws, ensuring consistency with the new scheduling framework in the CSA and the related import/export provisions, so that Schedule A substances are treated alongside Schedule I and II substances in the broader regulatory scheme.
Sentencing review
This section defines a process for potential sentence reductions if scheduling changes occur for a Schedule A substance that was involved in a covered offense. It enables petitioning courts for a reduced sentence and directs expedited hearings to reflect the descheduling or rescheduling in the original judgment.
Rules of construction
This section states that nothing in the act should limit existing authorities to prosecute analogue substances under current law or prevent the Attorney General from temporarily or permanently scheduling, rescheduling, or decontrolling substances under the CSA as of the day before enactment.
This bill is one of many.
Codify tracks hundreds of bills on Criminal Justice across all five countries.
Explore Criminal Justice in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Department of Justice and the Drug Enforcement Administration gain clearer scheduling authority to curb importation and distribution of Schedule A analogues.
- The Department of Health and Human Services (including the FDA) can weigh scientific input in permanent scheduling decisions and oversee research exemptions.
- Legitimate researchers and laboratories with registered import/export activities gain a compliant pathway to study Schedule A substances.
- Domestic manufacturers and suppliers that operate under strict Schedule A controls benefit from a clear regulatory framework that can deter illicit competition.
- Public health and safety organizations at federal and local levels benefit from stronger tools to reduce harm from synthetic analogues.
Who Bears the Cost
- Importers and exporters face new registration and recordkeeping requirements and potential compliance costs.
- Manufacturers, distributors, and retailers must adjust labeling and packaging to meet Schedule A requirements.
- Research institutions may incur administrative burdens to obtain and maintain registrations for Schedule A research.
- Federal and state agencies must administer the new scheduling regime, increasing oversight and enforcement costs.
- State and local law enforcement may experience higher caseloads tied to Schedule A regulatory actions and enforcement.
Key Issues
The Core Tension
Balancing rapid, preventative control of potentially dangerous synthetic analogues with the protection of legitimate research and industrial innovation, all while navigating scientific uncertainty and cross‑statutory complexity.
The SIMSA Act introduces significant preemptive controls on synthetic analogue substances, which could risk overbreadth if structural similarity or predicted CNS effects are interpreted broadly. The temporary scheduling mechanism and the dual pathway to permanent scheduling—subject to HHS input—create potential for regulatory uncertainty during the transition period, particularly for researchers and industry players who rely on timing and certainty.
Labeling requirements based on IUPAC nomenclature could impose labeling challenges for complex or proprietary substances, and the crossing of multiple statutes through conforming amendments may complicate compliance for some entities. Finally, while the act emphasizes public health and safety, it also raises questions about how broadly “substantially similar” structures should be construed and how the balance between rapid control and scientific validation will be achieved in practice.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.